Josh W. DiGiacomo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Josh W. DiGiacomo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Inês Godet
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, USA
18 shared publications - Daniele M. Gilkes
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, USA
12 shared publications Michael Trautmann-Rodriguez
8 shared publicationsDaniele M. Gilkes
7 shared publicationsI. Chae Ye
6 shared publications- Elana Judith Fertig
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
5 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Extracellular Matrix–Bound FGF2 Mediates Estrogen Receptor Signaling and Therapeutic Response in Breast Cancer
The extracellular matrix (ECM) is often unaccounted for in studies that consider the stromal contribution to cancer cell signaling and response to treatment. To investigate the influence of a fibrotic microenvironment, we use fibroblast-derived ECM scaffolds as a cell culture platform. We uncover that estrogen receptor–positive (ER+) breast cancer cells cultured within ECM-scaffolds have an increase in ER signaling that occurs via an MAPK-dependent, but estrogen-independent manner. The ECM acts as a reservoir by binding, enriching, and presenting growth factors to adjacent epithelial cells. We identified FGF2 as a specific ECM-bound factor that drives ER signaling. ER+ cells cultured on ECM matrices have reduced sensitivity to ER-targeted therapies. The sensitivity to ER-targeted therapy can be restored by inhibiting FGF2–FGFR1 binding. ECM–FGF2 complexes promote Cyclin D1 induction that prevents G1 arrest even in the presence of antiestrogens. This work demonstrates that the ECM can drive ER signaling and resistance to endocrine therapy, and suggests that patients with ER+ breast cancer that have high mammographic breast density may benefit from existing FGFR-targeted therapies.Implications:This work uncovers how the ECM may mediate signaling between growth factors and ER+ breast cancer cells to promote estrogen-independent ER signaling and resistance to endocrine therapy.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Extracellular Matrix–Bound FGF2 Mediates Estrogen Receptor Signaling and Therapeutic Response in Breast Cancer
The extracellular matrix (ECM) is often unaccounted for in studies that consider the stromal contribution to cancer cell signaling and response to treatment. To investigate the influence of a fibrotic microenvironment, we use fibroblast-derived ECM scaffolds as a cell culture platform. We uncover that estrogen receptor–positive (ER+) breast cancer cells cultured within ECM-scaffolds have an increase in ER signaling that occurs via an MAPK-dependent, but estrogen-independent manner. The ECM acts as a reservoir by binding, enriching, and presenting growth factors to adjacent epithelial cells. We identified FGF2 as a specific ECM-bound factor that drives ER signaling. ER+ cells cultured on ECM matrices have reduced sensitivity to ER-targeted therapies. The sensitivity to ER-targeted therapy can be restored by inhibiting FGF2–FGFR1 binding. ECM–FGF2 complexes promote Cyclin D1 induction that prevents G1 arrest even in the presence of antiestrogens. This work demonstrates that the ECM can drive ER signaling and resistance to endocrine therapy, and suggests that patients with ER+ breast cancer that have high mammographic breast density may benefit from existing FGFR-targeted therapies.Implications:This work uncovers how the ECM may mediate signaling between growth factors and ER+ breast cancer cells to promote estrogen-independent ER signaling and resistance to endocrine therapy.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental File 2 from Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes
Source code and searchable database
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental File 2 from Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes
Source code and searchable database
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Extracellular Matrix–Bound FGF2 Mediates Estrogen Receptor Signaling and Therapeutic Response in Breast Cancer
Genes Significantly Upregulated and Downregulated at least 2-fold by Both ECM Scaffold Culturing and BJ Fibroblast Coculture
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Extracellular Matrix–Bound FGF2 Mediates Estrogen Receptor Signaling and Therapeutic Response in Breast Cancer
Genes Significantly Upregulated and Downregulated at least 2-fold by Both ECM Scaffold Culturing and BJ Fibroblast Coculture